Table 2.

Ongoing clinical trials with neoadjuvant and adjuvant immune checkpoint inhibitors with or without chemotherapy adopted from neoadjuvant and adjuvant trials

Trial	NCT #	Therapy	Stages	n	Phase	Primary endpoint
Neoadjuvant
CANOPY N	03968419	Canakinumab or pembrolizumab (200 mg) or canakinumab + pembrolizumab × 2 cycles ➔ S	IB–IIIA	110	II	MPR
KEYNOTE 617	03425643	CT + pembrolizumab (200 mg) / placebo × 4 cycles ➔ S ➔ pembrolizumab / placebo × 13 cycles	IIB–IIIA	786	III	EFS, OS
CheckMate 816	02998528	CT + nivolumab (360 mg) × 3 cycles ➔ S vs. CT × 3 cycles ➔ S	IB–IIIA	350	III	EFS, MPR
IMpower 030	03456063	CT + atezolizumab (1200 mg) / placebo × 4 cycles ➔ S ➔ atezolizumab / placebo × 16 cycles	II–IIIB (cT3N2)	374	III	MPR
AEGEAN	03800134	CT + durvalumab (1,500 mg) / placebo Q3W × 4 cycles ➔ S ➔ durvalumab / placebo Q4W × 12 cycles	IIA–IIIB	300	III	MPR
Adjuvant
PEARLS	02504372	Pembrolizumab vs. placebo	IB–IIIA	1,080	III	DFS
BR31	02273375	Durvalumab vs. placebo	IB–IIIA	1,360	III	DFS in PD‐L1+ and all
ANVIL	02595944	Nivolumab vs. observation	IB–IIIA	903	III	DFS and OS
Impower 010	02486718	Atezolizumab vs. observation	IB–IIIA	1,280	III	DFS in II–IIIA, DFS in PD‐L1+, DFS in ITT
CANOPY‐A	03447769	Canakinumab vs. observation	IB–IIIA	1,500	III	DFS

Abbreviations: CT, chemotherapy; DFS, disease‐free survival; EFS, event free survival; ITT, intention to treat; MPR, major pathologic response; n, number; OS, overall survival; PD‐L1, programmed death‐ligand 1; Q3W, every 3 weeks; Q4W, every 4 weeks; S, surgery.